UroGen Pharma refinances $125 million debt facility, securing $200 million at 8.25% interest, extending maturity to 2030.
Quiver AI Summary
UroGen Pharma Ltd. has announced a refinancing agreement with Pharmakon Advisors, LP, which lowers the company's cost of capital and extends the loan's maturity period to Q1 2030. The amended loan agreement includes a senior secured term loan of up to $250 million, with an initial tranche of $200 million funded at closing to refinance an existing $125 million debt facility and provide additional non-dilutive capital. An additional $50 million is available for the company to draw upon before June 30, 2027, subject to customary conditions. The loans will bear a fixed interest rate of 8.25% and will not have financial covenants, enhancing UroGen's financial flexibility. This refinancing is seen as a strategic move to support the management of approved products and the advancement of UroGen's pipeline while strengthening its long-term growth strategy.
Potential Positives
- Opportunistic refinancing significantly reduces the company's cost of capital with a fixed interest rate of 8.25%.
- The refinancing extends the amortization period to Q1 2030, enhancing financial flexibility and stability.
- Access to an additional $50 million tranche until June 30, 2027, provides UroGen with non-dilutive capital for growth and product development.
- The absence of financial covenants associated with the amended loan provides UroGen with greater operational freedom and reduces constraints on its business activities.
Potential Negatives
- The 8.25% fixed interest rate on the new loan is relatively high, raising concerns about the overall cost of capital and potential financial strain on the company.
- The reliance on debt refinancing may indicate underlying financial instability or cash flow issues, as the company is refinancing a significant amount of its existing debt rather than generating additional equity.
- The absence of financial covenants in the amended loan agreement could be viewed negatively by investors, as it may signal a lack of fiscal discipline or oversight in the financial arrangements with Pharmakon.
FAQ
What is the significance of UroGen's refinancing agreement?
UroGen's refinancing agreement reduces its cost of capital and extends the amortization period to Q1 2030, providing financial flexibility.
How much capital was funded at closing with this refinancing?
The refinancing provided $200 million at closing to refinance an existing loan and offer additional non-dilutive capital.
What are the interest rates on UroGen's new loan facility?
All loans under the new agreement will accrue interest at a fixed rate of 8.25%.
When can UroGen access the additional $50 million tranche?
The additional $50 million tranche can be drawn at the Company’s discretion until June 30, 2027, subject to conditions.
Who acted as advisors during the refinancing transaction?
TD Cowen acted as the exclusive financial advisor, while Cooley LLP and Akin Gump served as legal advisors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$URGN Insider Trading Activity
$URGN insiders have traded $URGN stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 5 sales selling 18,244 shares for an estimated $411,819.
- JASON DREW SMITH (General Counsel) has made 0 purchases and 4 sales selling 8,999 shares for an estimated $176,308.
- CHRIS DEGNAN (Chief Financial Officer) sold 2,203 shares for an estimated $37,120
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$URGN Hedge Fund Activity
We have seen 82 institutional investors add shares of $URGN stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK removed 3,190,510 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $74,721,744
- AMERICAN CENTURY COMPANIES INC added 1,358,812 shares (+inf%) to their portfolio in Q4 2025, for an estimated $31,823,377
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND added 1,125,100 shares (+inf%) to their portfolio in Q4 2025, for an estimated $26,349,842
- MILLENNIUM MANAGEMENT LLC removed 849,785 shares (-57.9%) from their portfolio in Q4 2025, for an estimated $19,901,964
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 830,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $16,558,500
- MPM BIOIMPACT LLC added 806,378 shares (+597.3%) to their portfolio in Q4 2025, for an estimated $18,885,372
- FRONTIER CAPITAL MANAGEMENT CO LLC added 781,620 shares (+inf%) to their portfolio in Q4 2025, for an estimated $18,305,540
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$URGN Analyst Ratings
Wall Street analysts have issued reports on $URGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 10/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for $URGN, check out Quiver Quantitative's $URGN forecast page.
$URGN Price Targets
Multiple analysts have issued price targets for $URGN recently. We have seen 2 analysts offer price targets for $URGN in the last 6 months, with a median target of $36.5.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $33.0 on 01/23/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $40.0 on 10/27/2025
Full Release
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030
$200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital
Additional $50 million tranche available at Company’s discretion until June 30, 2027
PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, announced it has entered into an agreement with funds managed by Pharmakon Advisors, LP (Pharmakon) to revise the terms of its loan agreement entered into in March 2024.
On February 26, 2026, the Company entered into an amended and restated loan agreement with funds managed by Pharmakon for a senior secured term loan of up to $250 million in two tranches. The first tranche of $200 million was funded at closing to refinance the existing $125 million loan facility and provide additional non-dilutive capital. The second tranche of $50 million may be drawn at the Company’s discretion no later than June 30, 2027, subject to customary closing conditions. All outstanding loans with funds managed by Pharmakon will accrue interest at a fixed rate of 8.25% and be repaid in four equal quarterly payments commencing in the first quarter of 2030. There are no financial covenants associated with the amended loan.
“We are pleased to announce our expanded partnership with Pharmakon,” said Chris Degnan, Chief Financial Officer of UroGen. “This refinancing strengthens UroGen’s financial position by lowering our overall cost of capital, extending our maturity profile, and enhancing balance sheet flexibility. Importantly, it provides meaningful capital to support life-cycle management of our approved products and advancement of our pipeline. With a fixed interest rate and favorable long-dated maturity, this structure better positions UroGen to execute its long-term growth strategy and create value for both patients and shareholders.”
“Pharmakon is proud to continue supporting UroGen’s mission to address meaningful unmet needs in urothelial cancers,” said Martin Friedman, Principal at Pharmakon. “We have strong confidence in the company’s portfolio and commercial foundation, and this updated debt facility reflects our longstanding partnership and conviction in UroGen’s strategy as it enters its next phase of growth.”
TD Cowen acted as the exclusive financial advisor to UroGen on the transaction. Cooley LLP acted as legal advisor to UroGen. Akin Gump acted as legal advisor to Pharmakon.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma
About Pharmakon Advisors
Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed up to $11 billion across 68 investments.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the expected benefits of the amended and restated term loan agreement with Pharmakon, including its potential to strengthen UroGen’s financial position by lowering overall cost of capital, extending the maturity profile, enhancing balance sheet flexibility, and better positioning UroGen to execute on its long-term growth strategy; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs, other than mitomycin; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “anticipate,” “expect,” “may,” “potential,” “up to,” “will” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to UroGen’s products; risks related to our and our licensors’ ability to protect our respective patents and other intellectual property; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and ZUSDURI may not perform as expected; new data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market; the potential for payors to delay, limit or deny coverage for ZUSDURI; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, as updated by the Risk Factors section of UroGen’s Annual Report on Form 10-K for the year ended December 31, 2025, being filed with the SEC today, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083
